Actively Recruiting
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Led by Haihe Biopharma Co., Ltd. · Updated on 2026-01-30
100
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a an open-label, multinational, multicenter, single-arm Phase Ⅰb/Ⅱ Study to Evaluate Efficacy and Safety of Oral HH2853 in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma.
CONDITIONS
Official Title
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed diagnosis of relapsed or refractory Peripheral T-cell Lymphoma (PTCL) or Non-Hodgkin Lymphoma (NHL) with specific subtypes as defined in the protocol
- Received at least one but no more than five lines of prior systemic treatment for NHL (Phase Ib dose escalation)
- Received at least one line of prior systemic combination chemotherapy and at least one new drug therapy, with up to four prior treatment lines (Phase II)
- Availability of qualified tissue samples for pathological diagnosis by central laboratory
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of at least 3 months before starting HH2853 treatment
- Adequate bone marrow, liver, and renal functions
You will not qualify if you...
- Previous treatment with EZH2 or EZH1/2 inhibitors
- Central nervous system involvement
- Any history of bone marrow malignancy, including myelodysplastic syndrome (MDS)
- Use of potent CYP3A4 inducers or inhibitors within 1 week prior to the first dose of study drug
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sichuan Cancer Hospital
Chengdu, Chengdu, China
Actively Recruiting
Research Team
H
Haiying Jia
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here